0 -0.00423076923076927 -0.00423076923076927 -0.00423076923076927 0.00371794871794874 0.000128205128205133 0.0110790598290598 0.0218589743589744
Sign Up Today X
Thanks for submitting the form.
Stockreport

Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
MENLO PARK, Calif., February 04, 2026 BUSINESS WIRE )--Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the Vertex™ Pulmonary Embolectomy System in patients with acute, intermediate-risk pulmonary embolism (PE). The final subject was enrolled by Vikas Aggarwal, MD, Interventional Cardiologist at Henry Ford Hospital and the site's Principal Investigator. SPIRARE II (NCT06576427) is a prospective, single-arm, multicenter pivotal study that enrolled 123 patients across 23 sites in Europe and the U.S. Trial endpoints characterize the procedural and clinical performance of PE treatment with the Vertex system across measures of safety, right heart function, and clinical improvement from the time of the procedure to 30 days post-procedure. The Vertex system incorporate [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
MENLO PARK, Calif., February 04, 2026 BUSINESS WIRE )--Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the Vertex™ Pulmonary Embolectomy System in patients with acute, intermediate-risk pulmonary embolism (PE). The final subject was enrolled by Vikas Aggarwal, MD, Interventional Cardiologist at Henry Ford Hospital and the site's Principal Investigator. SPIRARE II (NCT06576427) is a prospective, single-arm, multicenter pivotal study that enrolled 123 patients across 23 sites in Europe and the U.S. Trial endpoints characterize the procedural and clinical performance of PE treatment with the Vertex system across measures of safety, right heart function, and clinical improvement from the time of the procedure to 30 days post-procedure. The Vertex system incorporate [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS